Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DuPont R&D Deal With Aventis Begins Strategy Of Merger Remnant Buying

Executive Summary

DuPont plans to participate in the current wave of pharmaceutical industry mergers by acquiring pieces of merging companies that have been made redundant rather than by a direct acquisition of its own.

You may also be interested in...



Aventis/DuPont

Talks discontinued regarding sale of Aventis' Romainville, France R&D facility to DuPont. The negotiation, which was initiated in March, would have included the sale of eight Aventis products and the transfer of a 300-person sales force to DuPont. Former DuPont Pharmaceuticals CEO Kurt Landgraf touted the agreement as a means for DuPont to benefit from consolidation without pursuing a merger of its own (1"The Pink Sheet" March 13, p. 19). Landgraf was replaced by Nicholas Teti in May. Aventis said it will seek a new buyer for the plant

Aventis/DuPont

Talks discontinued regarding sale of Aventis' Romainville, France R&D facility to DuPont. The negotiation, which was initiated in March, would have included the sale of eight Aventis products and the transfer of a 300-person sales force to DuPont. Former DuPont Pharmaceuticals CEO Kurt Landgraf touted the agreement as a means for DuPont to benefit from consolidation without pursuing a merger of its own (1"The Pink Sheet" March 13, p. 19). Landgraf was replaced by Nicholas Teti in May. Aventis said it will seek a new buyer for the plant

DuPont Pharmaceuticals' Teti Adds CEO To Title With Landgraf Resignation

DuPont President-Pharmaceuticals Nicholas Teti will add Chief Executive Officer to his title with the resignation of Kurt Landgraf, effective May 15.

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel